Related Experiment Videos
Fatal interaction between tranylcypromine and imipramine.
Wim Otte1, Tom K Birkenhager, Walter W van den Broek
1Emergis Centre for Mental Health, Goes, The Netherlands.
Summary
A patient taking tranylcypromine developed fatal serotonin syndrome after an accidental imipramine dose. This case highlights the severe risks of combining these medications.
Area of Science:
- Pharmacology
- Clinical Toxicology
- Neuroscience
Background:
- Tranylcypromine is a monoamine oxidase inhibitor (MAOI) used for depression.
- Imipramine is a tricyclic antidepressant (TCA).
- Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity.
Observation:
- A patient prescribed tranylcypromine received a single, accidental dose of imipramine.
- The patient subsequently exhibited symptoms consistent with serotonin syndrome.
Findings:
- The drug interaction between tranylcypromine and imipramine precipitated a fatal case of serotonin syndrome.
- Clinical manifestations and underlying pathophysiology of serotonin syndrome were observed.
Implications:
- This case underscores the critical importance of medication reconciliation to prevent dangerous drug interactions.
- Awareness of MAOI and TCA interactions is crucial for patient safety.
- Highlights the need for vigilant monitoring in patients with overlapping serotonergic and tricyclic antidepressant therapies.